[go: up one dir, main page]

FR2849599B1 - Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete - Google Patents

Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete

Info

Publication number
FR2849599B1
FR2849599B1 FR0300107A FR0300107A FR2849599B1 FR 2849599 B1 FR2849599 B1 FR 2849599B1 FR 0300107 A FR0300107 A FR 0300107A FR 0300107 A FR0300107 A FR 0300107A FR 2849599 B1 FR2849599 B1 FR 2849599B1
Authority
FR
France
Prior art keywords
kynurenine
diabetes
treatment
hydroxylase inhibitors
hydroxylase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0300107A
Other languages
English (en)
Other versions
FR2849599A1 (fr
Inventor
Valerie Autier
De Vacqueur Annick Arbellot
Micheline Kergoat
Gerard Moinet
Dominique Marais
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sante SAS
Original Assignee
Merck Sante SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sante SAS filed Critical Merck Sante SAS
Priority to FR0300107A priority Critical patent/FR2849599B1/fr
Priority to FR0314263A priority patent/FR2849598B1/fr
Priority to CA2512563A priority patent/CA2512563C/fr
Priority to AT03789341T priority patent/ATE457725T1/de
Priority to MXPA05007292A priority patent/MXPA05007292A/es
Priority to PCT/EP2003/014538 priority patent/WO2004060368A1/fr
Priority to CNA2003801084521A priority patent/CN1735410A/zh
Priority to PL378212A priority patent/PL378212A1/pl
Priority to ES03789341T priority patent/ES2339656T3/es
Priority to RU2005125086/04A priority patent/RU2005125086A/ru
Priority to KR1020057012707A priority patent/KR20050090447A/ko
Priority to EP03814462A priority patent/EP1581216A1/fr
Priority to CNA2003801084540A priority patent/CN1735411A/zh
Priority to MXPA05007293A priority patent/MXPA05007293A/es
Priority to JP2004564204A priority patent/JP4813800B2/ja
Priority to AU2003296679A priority patent/AU2003296679A1/en
Priority to BR0317950-8A priority patent/BR0317950A/pt
Priority to RU2005125085/15A priority patent/RU2351329C2/ru
Priority to EP03789341A priority patent/EP1581215B1/fr
Priority to US10/541,493 priority patent/US20060052456A1/en
Priority to DE60331359T priority patent/DE60331359D1/de
Priority to KR1020057012652A priority patent/KR20050090443A/ko
Priority to US10/541,377 priority patent/US7727977B2/en
Priority to PL03376017A priority patent/PL376017A1/xx
Priority to AU2003293937A priority patent/AU2003293937B2/en
Priority to BR0317947-8A priority patent/BR0317947A/pt
Priority to PCT/EP2003/014539 priority patent/WO2004060369A1/fr
Priority to JP2004564203A priority patent/JP2006515594A/ja
Priority to CA002512558A priority patent/CA2512558A1/fr
Priority to TW093100159A priority patent/TW200503676A/zh
Priority to TW093100157A priority patent/TW200418820A/zh
Priority to ARP040100025A priority patent/AR042712A1/es
Priority to ARP040100024A priority patent/AR043327A1/es
Publication of FR2849599A1 publication Critical patent/FR2849599A1/fr
Priority to ZA200506257A priority patent/ZA200506257B/en
Priority to ZA200506252A priority patent/ZA200506252B/en
Application granted granted Critical
Publication of FR2849599B1 publication Critical patent/FR2849599B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
FR0300107A 2003-01-07 2003-01-07 Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete Expired - Fee Related FR2849599B1 (fr)

Priority Applications (35)

Application Number Priority Date Filing Date Title
FR0300107A FR2849599B1 (fr) 2003-01-07 2003-01-07 Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete
FR0314263A FR2849598B1 (fr) 2003-01-07 2003-12-04 Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
DE60331359T DE60331359D1 (de) 2003-01-07 2003-12-18 Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes
MXPA05007292A MXPA05007292A (es) 2003-01-07 2003-12-18 Uso de inhibidores de quinurenina 3-hidroxilasa para el tratamiento de la diabetes.
PCT/EP2003/014538 WO2004060368A1 (fr) 2003-01-07 2003-12-18 Inhibiteurs de kynurenine 3-hydroxylase pour le traitement de diabetes par l'augmentation du nombre des ilots de cellules de langerhans
CNA2003801084521A CN1735410A (zh) 2003-01-07 2003-12-18 用于通过增加胰岛细胞的数量来治疗糖尿病的犬尿氨酸3－羟基化酶抑制剂
PL378212A PL378212A1 (pl) 2003-01-07 2003-12-18 Inhibitory 3-hydroksylazy kynureninowej do leczenia cukrzycy
ES03789341T ES2339656T3 (es) 2003-01-07 2003-12-18 Inhibidores de la quinurenina 3-hidroxilasa para el tratamiento de la diabetes.
RU2005125086/04A RU2005125086A (ru) 2003-01-07 2003-12-18 Ингибиторы кинуренин 3-гидроксилазы для лечения диабета путем повышения количества островков клеток лангерганса
KR1020057012707A KR20050090447A (ko) 2003-01-07 2003-12-18 당뇨병 치료용 키뉴레닌 3-하이드록실라제 저해제
US10/541,377 US7727977B2 (en) 2003-01-07 2003-12-18 Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes
CNA2003801084540A CN1735411A (zh) 2003-01-07 2003-12-18 用于治疗糖尿病的犬尿氨酸3－羟基化酶抑制剂
MXPA05007293A MXPA05007293A (es) 2003-01-07 2003-12-18 Uso de inhibidores de quinurenina 3-hidroxilasa para el tratamiento de la diabetes por incremento de la cantidad de celulas de los islotes de langerhans.
JP2004564204A JP4813800B2 (ja) 2003-01-07 2003-12-18 糖尿病を治療するためのキヌレニン３−ヒドロキシラーゼ阻害剤
AU2003296679A AU2003296679A1 (en) 2003-01-07 2003-12-18 Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells
BR0317950-8A BR0317950A (pt) 2003-01-07 2003-12-18 Inibidores de quinurrenina 3-hidroxilase para o tratamento de diabetes por aumento do número de ilhotas de células de langerhans
RU2005125085/15A RU2351329C2 (ru) 2003-01-07 2003-12-18 Ингибиторы кинуренин 3-гидроксилазы для лечения диабета
EP03789341A EP1581215B1 (fr) 2003-01-07 2003-12-18 Inhibiteurs de la kynurenine 3-hydroxylase pour le traitement du diabete
CA2512563A CA2512563C (fr) 2003-01-07 2003-12-18 Inhibiteurs de la kynurenine 3-hydroxylase pour le traitement du diabete
KR1020057012652A KR20050090443A (ko) 2003-01-07 2003-12-18 랑게르한스섬 세포 수를 증가시킴으로써 당뇨병을 치료하는키뉴레닌-３-하이드록실라제 저해제
AT03789341T ATE457725T1 (de) 2003-01-07 2003-12-18 Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes
EP03814462A EP1581216A1 (fr) 2003-01-07 2003-12-18 Inhibiteurs de kynurenine 3-hydroxylase pour le traitement de diabetes par l augmentation du nombre des ilots de cellules de langerhans
PL03376017A PL376017A1 (en) 2003-01-07 2003-12-18 Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells
AU2003293937A AU2003293937B2 (en) 2003-01-07 2003-12-18 Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes
BR0317947-8A BR0317947A (pt) 2003-01-07 2003-12-18 Inibidores de quinurenina 3-hidroxilase para o tratamento de diabetes
PCT/EP2003/014539 WO2004060369A1 (fr) 2003-01-07 2003-12-18 Inhibiteurs de la kynurenine 3-hydroxylase pour le traitement du diabete
JP2004564203A JP2006515594A (ja) 2003-01-07 2003-12-18 ランゲルハンス島細胞数を増加させることによって糖尿病を治療するためのキヌレニン３−ヒドロキシラーゼ阻害剤
CA002512558A CA2512558A1 (fr) 2003-01-07 2003-12-18 Inhibiteurs de kynurenine 3-hydroxylase pour le traitement de diabetes par l'augmentation du nombre des ilots de cellules de langerhans
US10/541,493 US20060052456A1 (en) 2003-01-07 2003-12-18 Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells
TW093100159A TW200503676A (en) 2003-01-07 2004-01-05 Use of kynurenine 3-hydroxylase inhibitors for the treatment of diabetes
TW093100157A TW200418820A (en) 2003-01-07 2004-01-05 Use of kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of Langerhans cells
ARP040100025A AR042712A1 (es) 2003-01-07 2004-01-07 Uso de inhibidores de quinurenina 3- hidroxilasa para el tratamiento de la diabetes por incremento de la cantidad de celulas de los islotes de langerhans
ARP040100024A AR043327A1 (es) 2003-01-07 2004-01-07 Uso de inhibidores de quinurenina 3- hidroxilasa para el tratamiento de la diabetes
ZA200506257A ZA200506257B (en) 2003-01-07 2005-08-04 Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes
ZA200506252A ZA200506252B (en) 2003-01-07 2005-08-04 Kynunerine 3-hydroxylase inhibitors for the treatment of diabets by increasing the number of islets of Langerhans cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0300107A FR2849599B1 (fr) 2003-01-07 2003-01-07 Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete

Publications (2)

Publication Number Publication Date
FR2849599A1 FR2849599A1 (fr) 2004-07-09
FR2849599B1 true FR2849599B1 (fr) 2006-12-29

Family

ID=32524724

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0300107A Expired - Fee Related FR2849599B1 (fr) 2003-01-07 2003-01-07 Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete

Country Status (3)

Country Link
CN (2) CN1735410A (fr)
FR (1) FR2849599B1 (fr)
ZA (2) ZA200506252B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103159618B (zh) * 2011-12-09 2016-05-11 天津市国际生物医药联合研究院有限公司 4-羰基-2-丁烯酸类化合物及其用途
EP2970092B1 (fr) * 2013-03-14 2016-12-14 Bristol-Myers Squibb Company Modulateurs de récepteurs gpr120 à base d'acide bicyclo [2.2.1]

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0885869A1 (fr) * 1996-02-19 1998-12-23 Japan Tobacco Inc. Agent therapeutique contre le diabete
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
FR2752422B1 (fr) * 1996-08-16 1998-11-06 Lipha Composition pharmaceutique contenant des acides 4-oxo-butanoiques
US6288063B1 (en) * 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds

Also Published As

Publication number Publication date
FR2849599A1 (fr) 2004-07-09
CN1735410A (zh) 2006-02-15
ZA200506257B (en) 2006-05-31
CN1735411A (zh) 2006-02-15
ZA200506252B (en) 2006-05-31

Similar Documents

Publication Publication Date Title
FR22C1033I1 (fr) Utilisation de dihydroimidazolones pour le traitement des chiens
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
EP1501489A4 (fr) Polytherapie pour le traitement de cancer
FR15C0069I2 (fr) Formulation a usage topique d'ivermectine pour le traitement de conditions dermatologiques
EP1865976A4 (fr) Utilisation de peptide natriuretique pour le traitement d'une insuffisance cardiaque
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
EP1951272A4 (fr) Utilisation de lactobacillus pour le traitement d'infections virales
FR2846870B1 (fr) Materiel d'osteosynthese pour le traitement d'un cubitus"long"
EP1587502A4 (fr) Pansement pour blessure
EP1901733A4 (fr) Utilisation d'huperzine pour des pathologies
DK1575597T3 (da) Anvendelse af rimexolon til behandling af öjentörhed
FR2890306B1 (fr) Dispositif pour le traitement d'une poche vasculaire
EP1800606A4 (fr) Instrument de traitement pour opération de pontage d'artère coronarienne
EP1750513A4 (fr) Utilisation de ligands gpcr54 pour le traitement de l'infertilite
FR2844453B1 (fr) Utilisation de pre-biotiques pour la prevention de l'installation du diabete de type ii
EP1359885A4 (fr) Inhibiteurs de nos pour le traitement des rides
FR2835851B1 (fr) Composition pour le traitement d'alliages de magnesium
EP1572129A4 (fr) Derives d'amidine pour le traitement des amyloses
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
FR2849599B1 (fr) Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete
NO20042476L (no) Anvendelse av desoxypeganin for behandling av klinisk depresjon
EP1580196A4 (fr) Proteine de surveillance destinee a mesurer le traitement d'une proteine
FR2834887B1 (fr) Utilisation d'un extrait d'artemia pour le traitement des peaux agees

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20081029